The estimated Net Worth of Ian Taylor is at least $6.47 Milion dollars as of 23 February 2024. Ian Taylor owns over 1,701 units of Arvinas Inc stock worth over $3,671,823 and over the last 6 years he sold ARVN stock worth over $814,632. In addition, he makes $1,985,420 as Chief Scientific Officer at Arvinas Inc.
Sign up
Ian Taylor ARVN stock SEC Form 4 insiders trading
Ian has made over 17 trades of the Arvinas Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,701 units of ARVN stock worth $80,032 on 23 February 2024.
The largest trade he's ever made was exercising 25,000 units of Arvinas Inc stock on 5 April 2021 worth over $400,000. On average, Ian trades about 7,259 units every 81 days since 2018. As of 23 February 2024 he still owns at least 147,522 units of Arvinas Inc stock.
You can see the complete history of Ian Taylor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ian Taylor biography
Dr. Ian Taylor Ph.D. is Chief Scientific Officer of the company. Dr. Taylor served as our Senior Vice President, Biology from January 2018 to March 2019, Vice President, Biology from August 2016 through December 2017, and Vice President, Pharmacology and Translational Medicine from June 2016 to July 2016. Immediately prior to joining Arvinas, Dr. Taylor served as Senior Director, Early Development Team Leader at Pfizer Inc., a biopharmaceutical company, from February 2007 to May 2016. Dr. Taylor holds a Ph.D. in molecular biology and genetics from Harvard University and a B.A. in Biochemistry from Bowdoin College.
What is the salary of Ian Taylor?
As the Chief Scientific Officer of Arvinas Inc, the total compensation of Ian Taylor at Arvinas Inc is $1,985,420. There are 2 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of $5,485,840.
How old is Ian Taylor?
Ian Taylor is 57, he's been the Chief Scientific Officer of Arvinas Inc since 2019. There are 9 older and 9 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
What's Ian Taylor's mailing address?
Ian's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN, CT, 06511.
Insiders trading at Arvinas Inc
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe a Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
What does Arvinas Inc do?
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
What does Arvinas Inc's logo look like?
Complete history of Ian Taylor stock trades at Arvinas Inc
Arvinas Inc executives and stock owners
Arvinas Inc executives and other stock owners filed with the SEC include:
-
John Houston,
President, Chief Executive Officer, Director -
Sean Cassidy,
Chief Financial Officer -
Ian Taylor,
Chief Scientific Officer -
Ronald Peck,
Chief Medical Officer -
Dr. John G. Houston Ph.D.,
CEO, Pres & Director -
Dr. Ronald A. Peck,
Chief Medical Officer -
Dr. Ian Taylor Ph.D.,
Chief Scientific Officer -
Sean A. Cassidy CPA, M.B.A., CPA,
CFO & Treasurer -
Laurie Smaldone Alsup,
Independent Director -
Leslie Norwalk,
Independent Director -
Timothy Shannon,
Independent Chairman of the Board -
Bradley Margus,
Independent Director -
Briggs Morrison,
Independent Director -
Liam Ratcliffe,
Independent Director -
Edward Kennedy,
Independent Director -
Wendy Dixon,
Director -
Linda Bain,
Director -
Steve Weiss,
VP of HR -
Dr. Randy Teel Ph.D.,
Sr. VP of Corp. & Bus. Devel. -
Dr. Robert Kleinfield,
Chief Devel. Officer -
Matthew Batters J.D.,
Gen. Counsel -
Jeff Boyle,
VP of Investor Relations -
Dr. Craig M. Crews,
Founder, Chief Scientific Advisor & Member of Scientific Advisory Board -
Ventures Iii, L.P.5 Am Part...,
-
David K Loomis,
Chief Accounting Officer -
Sunil Agarwal,
Director -
Ix L.P.Canaan Partners Ix L...,
-
Capital Management, L.P.Ra ...,
-
Jakob Loven,
Director -
Andrew Crew,
See Remarks -
Ventures Iii, L.P.5 Am Co I...,
-
James E Deerfield Mgmt L.P....,
-
Craig Martin Crews,
10% owner -
Kush Parmar,
Director -
Angela M Cacace,
Chief Scientific Officer -
John D Young,
Director -
Everett Cunningham,
Director -
Noah Berkowitz,
Chief Medical Officer -
Randy Teel,
Int. Chief Financial Officer